Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rolofylline in refractory CHF
NCT00159627Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rolofylline in heart failure (HF) (5 arms), sponsored by Merck & Co. Primary endpoint: Change in urine volume from baseline at 6 hours. Started Aug 2004; status: completed.
02
Drugs
rolofylline
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00159627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00159627.